SPEDOX-6

SPEDOX-6 is a novel formulation of doxorubicin, an anthracycline chemotherapeutic, encapsulated by a single human serum albumin (HSA) protein shell. This encapsulation increases the selective uptake of doxorubicin by rapidly dividing cells, such as cancer cells, while reducing its uptake—and thus toxicity—by non-proliferative cells like cardiomyocytes. The encapsulation leverages the tumor’s high albumin consumption, enhancing targeted delivery, antitumor efficacy, and pharmacokinetic profile, with marked reduction in cardiotoxicity. Developed and tested by a collaboration including Cedars-Sinai Medical Center and Sunstate Biosciences, SPEDOX-6 is currently advancing to early-phase human clinical trials for cancer treatment, with preclinical data supporting superior safety and efficacy compared to unencapsulated doxorubicin[1][2][3][4][5][6][8].

Brand names

SPEDOX-6SPEDOX6SPEDOX 6

Other names

single protein encapsulated doxorubicinHSA-encapsulated doxorubicin